← Back to Search

Alkylating agents

Ca2+/Mg2+pre & post cycle 2 for Colorectal Cancer

Phase 1
Waitlist Available
Research Sponsored by AHS Cancer Control Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post cycle 2 and 3
Awards & highlights

Study Summary

The investigators hypothesize that Ca2+/MG2+ infusions will not have a significant effect on oxaliplatin pharmacokinetics.

Eligible Conditions
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post cycle 2 and 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and post cycle 2 and 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary objective of this study is to determine potential pharmacokinetic interactions between oxaliplatin and calcium and magnesium.

Trial Design

2Treatment groups
Active Control
Group I: Ca2+/Mg2+pre & post cycle 2Active Control1 Intervention
Arm B:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 2
Group II: Ca2+/Mg2+ pre & post cycle 1Active Control1 Intervention
Arm A:Ca2+/Mg2+: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1

Find a Location

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor
182 Previous Clinical Trials
36,197 Total Patients Enrolled
Michael Sawyer, MDStudy ChairAlberta Health services
13 Previous Clinical Trials
658 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~1 spots leftby Apr 2025